Current BMI-based eligibility criteria for semaglutide may systematically exclude Asian Americans who develop metabolic disease at lower body weights.
Asians develop metabolic syndrome at lower BMIsStandard semaglutide eligibility (BMI ≥30) may exclude Asian patients who already have visceral obesity and metabolic dysfunction
What the researchers found
This review argues that Asian Americans may be unfairly excluded from semaglutide prescriptions for chronic weight management because current eligibility criteria rely on BMI thresholds that don't account for ethnicity-specific differences in body composition. Asians develop metabolic syndrome — including visceral fat accumulation, insulin resistance, and cardiovascular risk — at lower BMI levels than other populations. The review calls for integrating visceral fat measurements and other ethnicity-specific risk predictors into the diagnostic and prescribing framework for metabolic syndrome and semaglutide access.
Why it matters
Semaglutide prescribing guidelines use BMI cutoffs (typically ≥30 or ≥27 with comorbidities) that were developed primarily in Western populations. Asian populations develop metabolic complications at lower BMIs, meaning many Asian Americans with genuine metabolic syndrome may not qualify for semaglutide. This review highlights a significant health equity issue: standard prescription criteria may systematically deny effective treatment to an entire population group.
How the study worked
Critical narrative review of existing literature on semaglutide's use for chronic weight management, metabolic syndrome diagnosis, and ethnicity-specific body composition differences in Asian populations. No new data were collected.
Who was studied
Review focused on Asian American populations and semaglutide prescribing criteria
What this study cannot tell us
This is a narrative review published in Cureus (an open-access journal with less rigorous peer review than top-tier journals). It does not provide new data or systematic analysis. The arguments, while clinically important, are based on synthesized existing evidence rather than original research specifically testing different BMI thresholds for semaglutide in Asian populations.
How to read the evidence
Narrative review synthesizing existing evidence. Raises an important clinical and equity question but does not provide original data. Published in Cureus, which has a faster but less rigorous peer review process.
When this study was published
Published in 2024 in Cureus. The equity concerns raised are current and directly relevant to ongoing GLP-1 prescribing debates.
The bigger picture
The debate over BMI's limitations is well-established in medicine, but this review connects it directly to GLP-1 drug access — a timely issue given semaglutide's enormous demand and ongoing shortages. As GLP-1 agonists become central to metabolic disease treatment, ensuring equitable access across ethnic groups becomes a major public health concern. This also connects to the broader movement toward precision medicine, where treatment criteria account for individual and population-level differences rather than one-size-fits-all thresholds.
Questions still open
- Should semaglutide prescribing criteria use lower BMI thresholds for Asian patients, as WHO already recommends for obesity classification?
- Would incorporating waist circumference or visceral fat imaging improve prescribing equity across ethnic groups?
- Has the semaglutide shortage disproportionately affected Asian Americans who fall outside standard eligibility?
Common questions
Why would Asian patients need semaglutide at lower BMIs?
Does WHO already recognize different BMI thresholds for Asians?
Read the original research
Reconsidering Semaglutide Use for Chronic Obesity in Patients of Asian Descent: A Critical Review.
Cureus, 16(11), e73111
Citation
Lu, Jenny; Williams, Grace; Fanning, Stacey. (2024). Reconsidering Semaglutide Use for Chronic Obesity in Patients of Asian Descent: A Critical Review.. Cureus, 16(11), e73111. https://doi.org/10.7759/cureus.73111